Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-world heart procedure blood thinner patterns under the microscope

NCT ID NCT05193019

Knowledge-focused Sponsor: Fundación EPIC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks how doctors in Spain use injectable blood thinners (cangrelor or GPIs) during heart procedures like stent placement. It includes 717 patients and will look at short-term outcomes like death, heart attack, stroke, and bleeding within 48 hours. The goal is to understand current practice and safety in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Parenteral antiplatelet agents (cangrelor or glycoprotein IIb/IIIa inhibitors)
What this could lead to
If successful, this could help doctors choose the best blood thinner for heart procedures, potentially reducing complications.
What could go wrong
This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to other countries or populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

717 people

The number who actually took part.

Started

Mar 2022

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing a PCI and use of a parenteral antiplatelet agent (GPIs or cangrelor)during the invasive procedure (PCI)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Undergoing a PCI * Use of a parenteral antiplatelet agent (GPIs or cangrelor)during the invasive procedure (PCI) Exclusion Criteria: * Blood dyscrasia, bleeding diathesis or active bleeding at the time of the index procedure. * Chronic oral anticoagulation. * Recent history of stroke, TIA (Transient Ischemic Attack)or intracranial bleeding (\<3 months prior to inclusion). * Severe anemia (Hb\<9g/dl) or platelet count \<100x106/ml at the time of the index procedure. * Any active neoplasm.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Ischemic heart disease

Contacts and locations

Locations

  • H.de Leon

    León, 24080, Spain

  • Hospital Central de La Defensa Gómez Ulla

    Madrid, 28047, Spain

  • Hospital Clinico Universitario Santiago de Compostela

    Santiago de Compostela, 15706, Spain

  • Hospital Clinico Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hospital Universitari Joan Xxiii

    Tarragona, 43005, Spain

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Hospital Universitario Lozano Blesa

    Zaragoza, 50009, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, 39008, Spain

  • Hospital Universitario de Cabueñes

    Gijón, 33394, Spain

  • Hospital Universitario de Cruces

    Barakaldo, 48903, Spain

  • Hospital Universitario de Navarra

    Pamplona, 31008, Spain

  • Hospital de Galdakao

    Galdakao, 48960, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.